Thomas L. Pile, PharmD, CDCES

home / authors / thomas-l-pile-pharmd-cdces

Articles

Health care professional using electronic health record -- Image credit: Gorodenkoff | stock.adobe.com

The Impact and Potential of Digital Health Technologies

Craig Kimble, PharmD, MBA, MS, BCACP;Thomas L. Pile, PharmD, CDCES;Alberto Coustasse, DrPH, MD, MBA, MPH
July 22nd 2024

Innovations are expanding opportunities for care.

Read More

AI drug development clinical trial research

Optimizing Pharmaceutical Innovation Through AI: A Pathway to Expedited Drug Discovery and Development

Alberto Coustasse, DrPH, MD, MBA, MPH;Craig Kimble, PharmD, MBA, MS, BCACP;Vinay Penematsa, MD, MS;Thomas L. Pile, PharmD, CDCES
May 23rd 2024

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD